Multiple Myeloma News & Features
A genetic variation in the FOPNL gene can increase mortality for patients with multiple myeloma.
A new T cell receptor (TCR) therapy that utilizes a person's own immune system to recognize and destroy cancer cells demonstrated a clinical response in 80% of patients.
ISS plus chromosomal abnormalities detected by interphase fluorescent in situ hybridization offer prognostic value in newly-diagnosed multiple myeloma.
Multiple myeloma uses a trick akin to a wolf in sheep's clothing to grow in and spread to new bone sites.
Bortezomib-based vs non-bortezomib-based post-transplantation treatment in multiple myeloma patients: a systematic review and meta-analysis of Phase III randomized controlled trials
[Oncotargets and Therapy] This research examines the efficacy and safety of bortezomib-based vs non-bortezomib-based post-transplantation therapy in patients with multiple myeloma.
Multiple Myeloma Clinical Trials
- Overweight breast cancer survivors treated with tamoxifen may have higher risk for arm lymphedema
- Poor survival in multiple myeloma patients linked to genetic variation
- Unraveling of molecular changes in acute lymphoblastic leukemia (ALL) opens new treatment options
- Profile of neratinib and its potential in the treatment of breast cancer
- Religiousness and spirituality have a significant impact on cancer patients' overall health and outcomes
- Race and institutional factors play important roles in pharmacogenomics trial participation
- Research group looking to bring Cuba's lung cancer vaccine to the United States
- Patients with advanced cancer prefer open, effective communication
- 26 percent of senior oncology patients use alternative therapies
- Older, younger patients with metastatic pancreatic cancer have similar survival
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|